Healthcare · Pharmaceuticals & Biotechnology
QVM read Quality in motion Quality Strong, Valuation Expensive, Momentum Bullish
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company headquartered in Ahmedabad. Primarily engaged in the manufacturing of generic drugs, the company ranked 100th in the Fortune India 500 list in 2020.
Source: Wikipedia
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Ranks #4 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Filed | Person | Category | Type | Quantity | Value |
|---|---|---|---|---|---|
| 17 Nov 2025 | Jasodaben Babubhai Patel | Promoter group | Buy | 0 | ₹0 |
| 29 Mar 2024 | ZYDUS FAMILY TRUST | Promoter | Sell | 0 | ₹0 |
| 29 Mar 2024 | ZYDUS FAMILY TRUST | Promoter | Sell | 0 | ₹0 |
| 29 Mar 2024 | DEVAL DHIRAJBHAI SHAH | Immediate relative | Pledge Revoke | 0 | ₹2.94 L |
| 29 Mar 2024 | DEVAL DHIRAJBHAI SHAH | Immediate relative | Sell | 0 | ₹0 |
| 28 Mar 2024 | ZYDUS FAMILY TRUST | Promoter | Sell | 0 | ₹0 |
| 28 Mar 2024 | ZYDUS FAMILY TRUST | Promoter | Sell | 0 | ₹0 |
| 28 Mar 2024 | DEVAL DHIRAJBHAI SHAH | Immediate relative | Pledge | 0 | ₹9.42 L |
| 28 Mar 2024 | DEVAL DHIRAJBHAI SHAH | Immediate relative | Sell | 0 | ₹0 |
| 28 Mar 2024 | DEVAL DHIRAJBHAI SHAH | Immediate relative | Pledge Revoke | 0 | ₹1.53 L |
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 8 Mar 2006 | DEUTSCHE SECURITIES MAURI | Bulk | Sell | 327,475 | 565.5600 | BSE |
| 16 Apr 2004 | Govt.of Singapore Investm | Bulk | Buy | 491,703 | 536.0000 | BSE |
| 16 Apr 2004 | Carlson Fund | Bulk | Sell | 500,000 | 536.0700 | BSE |
| Ex-date | Subject | Per share (₹) | Record date |
|---|---|---|---|
| 24 Jul 2026 | Dividend - Re 1 Per Share | 1.0000 | 24 Jul 2026 |
| 25 Jul 2025 | Dividend - Rs 11 Per Share | 11.0000 | 25 Jul 2025 |
| 26 Jul 2024 | Dividend - Rs 3 Per Share | 3.0000 | 26 Jul 2024 |
| 28 Jul 2023 | Dividend - Rs 6 Per Share | 6.0000 | 28 Jul 2023 |
| 28 Jul 2022 | Dividend - Rs 2.50 Per Share | 2.5000 | 29 Jul 2022 |
| 28 Jul 2021 | Annual General Meeting/Dividend - Rs 3.50 Per Share | 3.5000 | — |
| 23 Mar 2020 | Interim Dividend - Rs 3.50 Per Share | 3.5000 | 24 Mar 2020 |
| 25 Jul 2019 | Annual General Meeting/Dividend - Rs 3.50 Per Share | 3.5000 | — |
| 31 Jul 2018 | Annual General Meeting/Dividend- Rs 3.50 Per Share (Purpose Revised) | 3.5000 | — |
| 16 Mar 2017 | Interim Dividend Rs 3.20 Per Share (Purpose Revised) | 3.2000 | 17 Mar 2017 |
Bonuses, splits, buybacks and other events. Dividends are listed separately above.
| Ex-date | Type | Subject |
|---|---|---|
| 6 Oct 2015 | SPLIT | Face Value Split (Sub-Division) - From Rs 5/- Per Share To Re 1/- Per Share |
| 5 Apr 2010 | BONUS | Bonus 1: 2 |
| 30 Aug 2006 | BONUS | Bonus 1:1 |
| — | NAME_CHANGE | Name changed from Cadila Healthcare Ltd. to Zydus Lifesciences Limited |
| 29 May 2026 | BUYBACK | Buy Back |
| 23 Feb 2024 | BUYBACK | Buy Back |
| 1 Jun 2022 | BUYBACK | Buyback |
| 12 Aug 2020 | OTHER | Annual General Meeting |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 11 Aug 2026 | Financial Results | Yes |
| 19 May 2026 | Buyback | — |
| 19 May 2026 | Financial Results/Dividend | Yes |
| 9 Feb 2026 | Financial Results | Yes |
| 6 Nov 2025 | Fund Raising | — |
Exchange disclosures (NSE and BSE), most recent first.
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Data unavailable.
Board of directors and corporate information →
Single-stock futures and a real listed options chain available for this stock -- OI buildup, PCR, Max Pain and Greeks are all on the full F&O page.
Part of: NIFTY 100, NIFTY 100, NIFTY 200, NIFTY 200, NIFTY 500, NIFTY 500, NIFTY NEXT 50, NIFTY NEXT 50, NIFTY PHARMA, NIFTY PHARMA
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
